Acromegaly
Pipeline by Development Stage
Drug Modality Breakdown
Endocrinology is a $1.4B mature market dominated by legacy products and characterized by significant patent cliff exposure in the near-term.
Key Trends
- Two blockbusters (FORTEO, SYNTHROID) approaching LOE with $780M combined spend
- Growth phase products (ORGOVYX, TYMLOS) entering peak revenue years through 2040
- Heavy trial activity (625 total) concentrated in Phase 3 and Phase 4 studies indicating established disease focus
Career Verdict
Endocrinology offers stability and specialized expertise but limited growth upside; best suited for professionals comfortable in mature markets seeking deep disease knowledge rather than explosive market expansion.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | FORTEO (TERIPARATIDE) | Eli Lilly and Company | $425M | 30% | LOE_APPROACHING | Declining | |
| 2 | SYNTHROID (LEVOTHYROXINE SODIUM) | AbbVie | $355M | 25% | LOE_APPROACHING | Declining | |
| 3 | ORGOVYX (RELUGOLIX) | Sumitomo Dainippon Pharma | $277M | 20% | PEAK | Stable | 11.4yr |
| 4 | TYMLOS (ABALOPARATIDE) | Radius Health | $198M | 14% | PEAK | Stable | 13.7yr |
Drug Class Breakdown
LOE approaching; potential for new mechanisms
Mature, multiple generics; limited differentiation
Growth trajectory through 2037
Stable; multiple biosimilars in market
Emerging niche for rare endocrine disorders
Career Outlook
StableEndocrinology offers deep specialization and stable employment but limited growth trajectory; market maturity and patent cliff exposure create restructuring risk for legacy product teams at large pharma. Career advancement depends on niche expertise (rare endocrine disorders, bone metabolism) and willingness to work at smaller or specialist biotech firms where hiring is concentrated. Compensation is moderate relative to other therapeutic areas, with Medical Affairs and Clinical Operations commanding premiums.
Breaking In
Prioritize roles at Neurocrine Biosciences or other specialist firms over large pharma to gain endocrinology depth; seek Clinical Operations or IT positions for better compensation and career stability.
For Experienced Professionals
Experienced professionals should pursue Medical Affairs or senior Clinical Operations roles (highest salaries) or consider pivoting to emerging indications (GnRH antagonists in non-prostate oncology, novel PTH mechanisms) to avoid legacy product decline.
In-Demand Skills
Best For
Hiring Landscape
Endocrinology hiring is concentrated at specialist biotech firms (Neurocrine: 126 jobs, 93% of available positions) rather than large pharma, indicating a niche market dynamic. IT roles dominate openings (51 jobs, $201K avg) followed by R&D (21 jobs, $120K avg), suggesting company-level digitalization and data infrastructure needs. Compensation ranges widely ($115K-$359K), with Medical Affairs offering premium salaries ($359K) but minimal openings (6 jobs).
By Department
Limited total opportunity (135 jobs) concentrated at one biotech firm signals a tight job market; IT and Clinical Operations offer best compensation, but specialized endocrinology roles are scarce.
On Market (3)
Approved therapies currently available
Competitive Landscape
13 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 3,297 patients across 50 trials
Pasireotide LAR and Pegvisomant Study in Acromegaly
Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
Ultrasound Guided Octreotide LAR Injection in Acromegaly
Effects of Sandostatin LAR® in Acromegaly
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Somatuline Autogel: Acromegaly Self/Partner Injection Study
Pegvisomant And Sandostatin LAR Combination Study
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
Octreotide Efficacy and Safety in First-line Acromegalic Patients
Preoperative Octreotide Treatment of Acromegaly
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
Long Term Study With B2036-PEG
Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
Estrogen Treatment in Acromegalic Women
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Related Jobs in Endocrinology
Director, Marketing Operations
Sr. Consultant, Data Analyst & Commercial Productivity
Area Business Manager - Central Alabama
Director, Quality Control
Associate Director, Pharmacovigilance (PV) Commercial Liaison, Global Clinical Safety and Pharmacovigilance
Quality Compliance Lead International
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.